Keam, B. and Machiels, J-P and Kim, H. R. and Licitra, L. and Golusinski, W. and Gregoire, V and Lee, Y. G. and Belka, C. and Guo, Y. and Rajappa, S. J. and Tahara, M. and Azrif, M. and Ang, M. K. and Yang, M-H and Wang, C-H and Ng, Q. S. and Wan Ishak, Wan Zamaniah and Kiyota, N. and Babu, S. and Yang, K. and Curigliano, G. and Peters, S. and Kim, T. W. and Yoshino, T. and Pentheroudakis, G. (2021) Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open, 6 (6). ISSN 2059-7029, DOI https://doi.org/10.1016/j.esmoop.2021.100309.
Full text not available from this repository.Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of squamous cell carcinoma (SCC) of the oral cavity, larynx, oropharynx and hypopharynx was published in 2020. It was therefore decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special, virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider the potential ethnic differences associated with the treatment of SCCs of the head and neck (SCCHN) in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with SCCHN (excluding nasopharyngeal carcinomas) representing the oncological societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter was discussed when appropriate. This manuscript provides a series of expert recommendations (Clinical Practice Guidelines) which can be used to provide guidance to health care providers and clinicians for the optimisation of the diagnosis, treatment and management of patients with SCC of the oral cavity, larynx, oropharynx and hypopharynx across Asia.
| Item Type: | Article |
|---|---|
| Funders: | ASCO AP Regional Council, Amgen Malaysia, Celgene International, Celgene Malaysia, DKSH, DKSH Malaysia, Daiichi-Sankyo and Sanofi, Debiopharm International SA, Doxa Pharma, ESMO Singapore Office, Eisai Malaysia, Elekta/Abex, Eli Lilly Malaysia, Exelixis Inc, Greater Petaling Cancer City Challenge UICC, IRX Therapeutics Inc., Ipsen Malaysia, Malaysian Oncological Society, Medpace Inc., Merck Biopharma, Merck Serono Malaysia, Merck-Serono, NEKTAR, Pfizer Malaysia, Phosplatin Therapeutics, RTP, Rakuten Medical, Roche Malaysia, Roche Spa and Buran, Scientific and Medical Division of ESMO, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, AstraZeneca, Bayer, Genentech, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi, Boehringer Ingelheim, Takeda Pharmaceutical Company, Janssen Pharmaceuticals, Merck KGaA, Merck Sharp and Dohme, Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, European Society for Medical Oncology, Ono Pharmaceutical |
| Uncontrolled Keywords: | ESMO; Guidelines; Head and neck; Pan-Asian; Squamous cell carcinoma; Treatment |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine > Clinical Oncology Department |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 20 Oct 2023 05:38 |
| Last Modified: | 20 Oct 2023 05:38 |
| URI: | http://eprints.um.edu.my/id/eprint/35301 |
Actions (login required)
 |
View Item |
